Newsletter Tool

Featured Story

Regeneron's COVID-19 antibodies rake in $2.6B, reflecting their market dominance and blowing away estimates

By Kevin Dunleavy

Regeneron reported second quarter sales of $2.59 billion for its COVID-19 antibody treatment REGEN-COV, propelling the company to $5.14 billion in revenue. The performance blew away the Wall Street estimates.

Cigna anticipates elevated claims costs for rest of 2021, execs say

By Paige Minemyer

Cigna posted $1.5 billion in profit in the second quarter of 2021, echoing its industry peers in seeing its earnings decline from Q2 2020.

Moderna, citing variants and waning immunity, expects COVID-19 boosters to become a fact of life

By Eric Sagonowsky

For anyone thinking aggressive COVID-19 vaccine rollouts would bring a quick end to the pandemic, Moderna has a word of caution. While U.S. authorities aren’t yet ready to recommend vaccine boosters, the company believes that add-on shots will become a fact of life for some as the virus sticks around and continues to put up a fight.

How COVID-19 impacted small businesses' health coverage

By Paige Minemyer

Despite the challenges presented by COVID-19, the small group insurance market remained stable over the past year, according to a new study.

Moderna abandons mid-stage mRNA cancer asset in favor of similar triple-attack candidate

By Annalee Armstrong

Moderna has ditched a phase 2 asset in development for solid tumors, lymphoma and ovarian cancer to instead focus on a similar therapy that could put up a triple attack. The biotech, of COVID-19 vaccine fame, revealed in a second-quarter earnings release that the standalone OX40L candidate mRNA-2416 will be shelved in favor of mRNA-2752.

COVID-19 Tracker